Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

/b>

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase Ib clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the latest information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel proteasome inhibitors, including a selective, oral proteaso
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... The DNA Spectrum Ancestry ... representation of history, migration, and culture. , Throughout ... family history stories stemming from Europe. His father passionately ... Pictures and 8mm home movies painted an elaborate picture ... and Steve ordered a test from DNA Spectrum to ...
(Date:7/22/2014)... SHENZHEN , Kina, 22. juli 2014 /PRNewswire/ ... et datterselskab af BGI, verdens største genomics-organisation, annoncerede ... exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform. ... for at levere patenterede sekvenseringsteknologier med 99,999 % ... blev købt af BGI i 2013. Mere end ...
(Date:7/22/2014)... Hussey Copper , a leader in copper manufacturing ... Pullman Regional Hospital,s conversion of more than 1,100 touch ... at a nominal cost.  This reasonably priced surface kills ... within 2 hours of exposure 1 and will aid ... in its facilities. Pullman Regional Hospital, in ...
(Date:7/22/2014)... July 22, 2014 Quorum Review IRB, the ... for large clinical trials called Quick Step™ . The ... to address the research industry’s need for seamless study start-up ... is available for studies planning 50 or more North American ... planned North American site count of 80 or more. Qualifying ...
Breaking Biology Technology:DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3
... N.Y. Whoever penned the old adage "a watched pot ... a pot lined with copper nanorods. , A new study ... an invisible layer of the nanomaterials to the bottom of ... required to bring water to boil. This increase in efficiency ...
... of Standards and Technology (NIST) have developed a ... magnetic materials such as nickel or nickel-iron alloys ... process, described in a recent paper,* could enable ... devices. , The NIST team also demonstrated that ...
... Inc.,("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: ... announced the results,of the Annual Shareholders Meeting held ... were 48,663,865 shares equaling 69.81% of the outstanding ... following,eight persons to serve as members of the ...
Cached Biology Technology:On the boil: New nano technique significantly boosts boiling efficiency 2On the boil: New nano technique significantly boosts boiling efficiency 3New process creates 3-D nanostructures with magnetic materials 2
(Date:7/22/2014)... In contrast to their negative reputation as disease ... and evolutionary functions that help to shape the ... new report by the American Academy of Microbiology. ... influence all life forms on the planet, from ... and driving major speciation events," states Marilyn Roossinck ...
(Date:7/22/2014)... N.C. In a cost-effectiveness analysis of commercial diet ... drug Qsymia showed the best value for the money. ... but was also the most expensive option tested, according ... Medical School. , The findings, published in the June ... information on the health and weight-loss benefits per dollar ...
(Date:7/22/2014)... China July 22, 2014 BGI Tech ... BGI, the world,s largest genomics organization, announced today ... exome sequencing service based on Complete Genomics, industry-leading ... analysis and SNP validation, and is available at ... Complete Genomics, highly regarded in the industry for ...
Breaking Biology News(10 mins):Report on viruses looks beyond disease 2Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2
... has always depended on harvesting from nature for food ... for technological ideas. Indeed, the guiding principle behind ... evolutionary process has already performed innumerable experiments over many ... Cheryl Hayashi will give a free public ...
... a stubby tail: an odd-looking mouse discovered through a U.S. government ... and an extra set of ribs in its neck and ... at the University of California, San Francisco has now spilled the ... have uncovered a new wrinkle in the genetic code an ...
... the Max Planck Society (MPG; President Peter ,Gruss) signed ... collaboration by ,establishing a joint research center for systems ... systematic understanding of biological systems from a chemistry perspective. ... together the RIKEN Advanced Science Institute,s ,natural chemical compounds ...
Cached Biology News:How nature's best ideas inspire innovative new technologies 2Mutant mouse reveals new wrinkle in genetic code, say UCSF scientists 2Mutant mouse reveals new wrinkle in genetic code, say UCSF scientists 3
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... to Human Cytokeratin TYPE II Reacts ... keratins. Including epidermal cell keratin of 86 ... and 67kD. Broad keratin reactivity is found ... Immunogen: Human epidermal ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
Biology Products: